CEL-SCI Home Page
preload preload

February 2016

CEL-SCI CEO on Fox

Press Releases

Corporate Presentations

Press Releases

July 6, 2017
NEW STORY CEL-SCI Extends the Expiration Date of Series DD Warrants Issued in December 2016

June 12, 2017
NEW STORY CEL-SCI Announces Reverse Stock Split

June 8, 2017
NEW STORY CEL-SCI Announces New Data for Its Rheumatoid Arthritis Vaccine Candidate Published in Peer Reviewed Journal

June 7, 2017
NEW STORY CEL-SCI Extends the Expiration Date of Series DD Warrants Issued in December 2016

June 5, 2017
NEW STORY CEL-SCI Submits FDA Response for Its Phase 3 Head and Neck Cancer Trial

May 24, 2017
NEW STORY CEL-SCI Corporation Releases Letter to Shareholders

May 16, 2017
NEW STORY CEL-SCI Scientist Presents At AAI - IMMUNOLOGY 2017 Meeting

May 12, 2017
NEW STORY CEL-SCI Announces Change to the Date of Its Annual Meeting

May 10, 2017
NEW STORY CEL-SCI Corporation Reports Second Quarter Fiscal Year 2017 Financial Results

May 1, 2017
NEW STORY CEL-SCI Announces $1.51 Million Registered Direct Offering

April 28, 2017
NEW STORY CEL-SCI Receives Intent to Grant Notice for New Multikine Patent from the European Patent Office

April 24, 2017
NEW STORY CEL-SCI Corporation Releases Letter to Shareholders

April 12, 2017
NEW STORY CEL-SCI Scientist Presents at the World Vaccine Congress

March 9, 2017
NEW STORY CEL-SCI Announces $1.5 Million Registered Direct Offering

March 6, 2017
NEW STORY CEL-SCI Gives Update on Partial Clinical Hold on Phase 3 Head and Neck Cancer Study with Multikine

February 27, 2017
NEW STORY CEL-SCI Announces That the NYSE MKT Approves Plan

February 21, 2017
NEW STORY CEL-SCI Scientist Presents New Findings for Rheumatoid Arthritis Treatment Vaccine at Conference

February 17, 2017
NEW STORY CEL-SCI Announces $1.0 Million Registered Direct Offering

February 9, 2017
NEW STORY CEL-SCI Corporation Reports First Quarter Fiscal 2017 Financial Results

December 20, 2016
NEW STORY CEL-SCI Announces Closing of Public Offering and Receives Audit Opinion with Going Concern Explanation

December 14, 2016
NEW STORY CEL-SCI Reports Fiscal 2016 Financial Results and Clinical & Corporate Developments

December 9, 2016
NEW STORY CEL-SCI Reports on NYSE MKT Noncompliance Notice and Compliance Plan

December 2, 2016
NEW STORY CEL-SCI Announces Pricing of $4.25 Million Public Offering of Common Stock and Warrants

December 1, 2016
NEW STORY CEL-SCI Announces Proposed Public Offering of Common Stock and Warrants

November 21, 2016
NEW STORY CEL-SCI Submits Response to FDA in Connection with Partial Clinical Hold on Phase 3 Clinical Trial

November 14, 2016
NEW STORY CEL-SCI Reports Preclinical Data Showing LEAPS Vaccine Is Successful In Treating Rheumatoid Arthritis

October 21, 2016
NEW STORY CEL-SCI Provides Update on Partial Clinical Hold on Phase 3 Clinical Trial

September 26, 2016
NEW STORY CEL-SCI Reports Clinical Hold on Head and Neck Cancer Study

September 6, 2016
NEW STORY CEL-SCI Announces Resignation of Its Founder for Health Reasons

September 2, 2016
NEW STORY CEL-SCI Reports Monthly Patient Enrollment in August for Its Phase 3 Head and Neck Cancer Trial

 

ADDITIONAL RELEASES
View All Corporate Press Releases


 

THE CEL-SCI STORY